Kornimate/medical-research-clean huggingface dataset:
effects of dietary heme/non-heme iron and helicobacter pylori (hp) infection on maternal iron-deficiency anemia and fetal growth outcomes

Conditions: Pregnancy; Helicobacter Pylori Infection; Iron-Deficiency Anemia

Summary: iron deficiency is considered one of the main nutritional deficiency disorders despite the apparent availability of a high-quality diet even in developed countries, and iron deficiency anemia (ida) is the most common form of anemia in the world. ida during pregnancy has been associated with adverse health consequences for both the mother and her developing fetus. helicobacter pylori (hp) may be the most common bacterial infection worldwide, infecting almost half of people in developed countries and 80% of people in developing countries. the available data on the prevalence of hp infection in taiwan population was 54.4%. we all know that infection with hp is strongly associated with peptic ulcer and gastric cancer, but recent evidence suggests that hp is associated with iron deficiency and anemia, although the mechanisms remain unclear. till now, only few previous studies specifically have addressed a potential role of hp infection on anemia or iron deficiency during pregnancy. our previous research showed, between the hp infection (+) and hp infection (-) gravidas, the associations between the hp infection and iron deficiency were stronger, although not statistically significant. this might be due to that we needed more cases and evidences to prove the relationship between maternal hp infection and serum iron, ferritin and hemoglobin levels, or we should further consider the interactions of the particular customs or diet preference of the taiwanese gravidas. this longitudinal study will recruit 140 women from the antenatal care clinics of e-da hospital to examine the association between hp infection and maternal ida. the standardized interviews of mothers (anthropometric data, socioeconomic status, medical history, obstetric history, alcohol consumption during pregnancy, and history and duration of iron supplementation during pregnancy) will be conducted, hp infection status will be determined by the urea breath test and igg enzyme immunoassay, and the measurement of hemoglobin, iron, and ferritin levels will be obtained 5 times at various antepartum and postpartum points of time during pregnancy (routine prenatal visits of 1st, 2nd, and 3rd trimester, puerperium and 2 weeks after delivery). we hope that we could investigate the possible role of hp infection in iron deficiency and iron-deficiency anemia during pregnancy in taiwan, and that early detection and treatment of anemia may reduce the risk of blood transfusion and perinatal and maternal mortality.


Eligibility criteria:
inclusion criteria: * pregnant ladies exclusion criteria: * thalassemia

Keywords: pregnancy anemia helicobacter pylori hemoglobin iron ferritin
a survey to evaluate diabetes management, control, complications and psychosocial aspects of diabetic patients in philippines

Conditions: Diabetes; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2

Summary: this study is conducted in asia. the aim of this observational study is to describe the diabetes management, control status and complication profile in a diabetic population of philippines.


Eligibility criteria:
inclusion criteria: * diabetic patients registered in the particular centre for more than 12 months * patients should have visited the centre at least once in the last 3-6 months apart from the initial visit * patients willing to sign informed consent form exclusion criteria: * repetition of any patient as patients should not be included twice for any reason * unwilling to participate or unable to comply with protocol requirements
effectiveness of pilates exercises applied to violinists with nonspecific neck pain

Conditions: Occupational Diseases

Summary: the aim of this study is to examine the effects of different pilates exercises on violinists experiencing non-specific neck pain

this study is planned as a randomized controlled study. participants will be divided into two groups, mat pilates and reformer pilates, between the ages of 18-50. participants will be asked to do the specified exercises for 6 weeks, 2 days a week and 45 minutes each session. individuals with psychological and physical disabilities to do regular exercise will not be included in the study. the researcher will prepare a personal information form to collect the sociodemographic characteristics of the participants. a visual analog scale will be used to measure pain intensity and recovery process, a neck pain and disability scale to evaluate neck function and disability status, and a neck disability questionnaire to determine the effect of neck pain on daily life activities. these questionnaires will be repeated at the beginning and end of the study.

Eligibility criteria:
inclusion criteria: * individuals between the ages of 18-50 * individuals who play the violin with neck pain * having received professional instrument training exclusion criteria * using medication * having any pathology that prevents exercise * having previously undergone upper extremity surgery

Keywords: violinist
functional communicative profile of children with down syndrome

Conditions: Down Syndrome

Summary: the aim of this study was to verify the use of communicative functions by children with ds in two interaction conditions: interaction with therapist and interaction with parent.

parents and caregivers' engagement on therapeutic process of children with down syndrome (ds) is important for language and communication development. the identification of the communicative skills presented by these children as well as the context influence in their performance as interlocutors, will contribute to the design of therapeutic interventions. pragmatics theories are helpful to language use studies, since it takes into account social and environmental aspects and considers adult-child interaction as a determinant factor for its occurrence.

Eligibility criteria:
inclusion criteria: * genetic diagnosis of down syndrome * good health conditions * normal results on audiologic evaluation * pediatric and ear, nose and throat periodic check ups. * attend speech-language therapy at the speech language pathology laboratory in syndromes and sensorimotor deficits (slpl-ssd) of the school of medicine of the university of são paulo. exclusion criteria: * submission to long term hospitalizations due to heart diseases and major respiratory airway infections, that may interfere in the child's global development * presence of visual or auditory important deficits

Keywords: down syndrome pragmatics language development
24-week study with open label extension of vx-509, an oral jak3 inhibitor, in subjects taking methotrexate

Conditions: Rheumatoid Arthritis

Summary: this study is designed to evaluate the safety and efficacy of vx-509, an oral jak3 inhibitor, for treatment of subjects with active ra who have had an inadequate response to methotrexate.

vx-509 is an oral, selective janus kinase 3 (jak3) inhibitor being developed by vertex. in autoimmune diseases, jak3 is an essential component of the immune signaling cascade. this cascade ultimately contributes to abnormal immune response that results in chronic inflammation and, in the case of rheumatoid arthritis (ra), irreversible damage to cartilage and bones. selective inhibition of jak3 offers a new disease modifying approach to the treatment of ra, and a broad range of other autoimmune diseases.

Eligibility criteria:
inclusion criteria: * male and female subjects, between 18 and 80 years of age (inclusive) * all subjects must have been diagnosed with ra * must have a swollen joint count of ≥6 out of 66 joints and tender joint count of ≥6 out of 68 joints * baseline crp level must be above the upper limit of normal * all subjects must have been receiving stable mtx coadministered with folic or folinic acid (at least 5 mg/week) * subjects may remain on 1 nonsteroidal anti-inflammatory medication during the study (aspirin ≤ 325 mg/day is allowed). * subjects must not have received prior treatment with a jak inhibitor * subjects who are on an additional nonbiologic dmard (e.g., sulfasalazine) must be willing to discontinue that dmard after signing consent, except for hydroxychloroquine * subjects may have received previous therapy with a single tnf inhibitor (e.g., etanercept, adalimumab, infliximab, golimumab, certolizumab pegol) * females must have a negative pregnancy test prior to study dosing * sexually active subjects and their partners must agree to contraceptive requirements exclusion criteria: * history or presence of a clinically significant medical disorder other than ra that, in the opinion of the investigator and medical monitor, would pose a risk to subject safety or interfere with the study evaluation, procedures, or completion. * subjects with inflammatory, rheumatological disorders other than ra * pregnant or nursing female subjects * subjects who have a female partner who is pregnant, nursing, or planning to become pregnant * subjects who have planned major surgery (e.g., joint replacement) or procedures during the study * history of drug abuse or positive drug screen * history of alcohol abuse or excessive alcohol consumption * history of tuberculosis (tb) infection of any kind (pulmonary or extrapulmonary, active or latent), regardless of history of anti-tb treatment.
atrial fibrillation and by-pass surgery

Conditions: Patients With Coronary Artery Disease Scheduled for by Pass Surgery

Summary: the aim of the study is to evaluate whether combined therapy with beta-blocker, amiodarone and statine is better than beta-blocker alone for the prevention of atrial fibrillation after coronary by-pass surgery.


Eligibility criteria:
inclusion criteria: * significant coronary disease, sinus rhythm exclusion criteria: * valvular disease, former by-pass surgery
vessel wall response of the bio-active-stent and everolimus-eluting stent assessed by optical coherence tomography

Conditions: Acute Coronary Syndrome

Summary: the purpose of the trial is to evaluate the completeness of struts coverage and vessel wall response (strut malapposition, neoin-timal formation) to the bio-active-stent (bas) versus ever-olimus-eluting stent (ees) implanted for the treatment of the culprit lesion in acute coronary syndrome.

a prospective, randomized and controlled study comparing the coverage of the bas and ees implanted in acute coronary syndrome. clinical follow-up at 1, 6, 12 and 18 months. oct analysis at the time of the 6 to 8 months follow-up.

Eligibility criteria:
inclusion criteria: * patient is ≥ 18 years old; * the patient is presenting with acute coronary syndrome, and according to hospital routine practice, eligible for percutaneous coronary intervention; * patient or the patient's legal representative has been informed of the nature of the study and has provided written informed consent as approved by the institutional ethics committee of the respective clinical site. exclusion criteria: * lesions in coronary artery bypass grafts * left main disease * killip class iii-iv * allergy to aspirin / thienopyridine * patient in anticoagulation therapy * no suitable anatomy for oct scan * ostial lesion * tortuosity anatomy * very distal lesion * vessel size \> 3.75 mm

Keywords: titanium everolimus oct acute coronary syndrome stent pci stenting
lutonix® global av registry investigating lutonix drug coated balloon for treatment of native and synthetic av fistulae

Conditions: Arteriovenous Fistula

Summary: the purpose of this registry is to enroll patients presenting with clinical and hemodynamic abnormalities in native or synthetic (grafts) arteriovenous (av) fistulae located in the arm. subjects will be treated with the lutonix dcb carrying the ce mark per current ifu and followed clinically for a minimum of 12 months.

this post market registry is intended to demonstrate safety and assess the clinical use and outcomes of the lutonix dcb in a heterogeneous patient population with dysfunctional native or synthetic av fistulae in real world clinical practice.

Eligibility criteria:
inclusion criteria: 1. male or non-pregnant, non-breastfeeding female ≥18 years of age; 2. patient is willing to provide informed consent, and is willing to comply with the protocol-required follow up visits; 3. native or synthetic (grafts) arteriovenous fistula located in the arm, including central veins, presenting with any clinical, physiological or hemodynamic abnormalities warranting angiographic imaging as defined in the k/doqi guidelines; and 4. lesion(s) can be treated with available lutonix dcb device size matrix per current ifu. exclusion criteria: patients will be excluded if any of the following conditions apply: 1. patient is currently participating in an investigational drug or device study which has not yet reached its primary endpoint or was previously enrolled into this registry (i.e. lutonix global av registry). 2. patient has a non-controllable allergy to contrast; or 3. patient has another medical condition that, which in the opinion of the investigator, may confound the data interpretation of is associated with a life expectancy insufficient to allow for completion of patient registry procedure and follow up.
efficacy and safety of new mometasone furoate nasal spray formulation in acute rhinosinusitis patients: a randomized clinical trial

Conditions: Acute Rhinosinusitis

Summary: seasonal and perennial allergic rhinitis, acute rhino sinusitis, and nasal polyposis are examples of common inflammatory disorders of the airway that significantly reduce patient health and quality of life. intranasal corticosteroids are advised as part of treatment plans for each of these illnesses since they help to reduce inflammation and thus symptoms. objective in order to assess the effectiveness and safety of a new nano formulation of mometasone furoate nano-nasal spray (fm-nns) for the treatment of allergic rhinitis. mometasone furoate nano-nasal spray (fm-nns) was compared with commercial available nasal spray named as mfns.

background seasonal and perennial allergic rhinitis, acute rhino sinusitis, and nasal polyposis are examples of common inflammatory disorders of the airway that significantly reduce patient health and quality of life. intranasal corticosteroids are advised as part of treatment plans for each of these illnesses since they help to reduce inflammation and thus symptoms. objective in order to assess the effectiveness and safety of a new nano formulation of mometasone furoate nano-nasal spray (fm-nns) for the treatment of allergic rhinitis. mometasone furoate nano-nasal spray (fm-nns) was compared with commercial available nasal spray named as mfns.

Eligibility criteria:
inclusion criteria: 1. children and adults of age (10-50) who had a diagnosis of rhinitis 2. ability and willingness to understand and provide informed consent. exclusion criteria: 1. known current pregnancy. 2. current hospitalization. 3. unable to complete online questionnaires or adhere to study requirements. 4. kidney failure or dialysis; severe liver disease or cirrhosis. 5. any parathyroid conditions. 6. known current pregnancy. 7. history of sars-cov-2 infection.
design of patient specific guides (psg) for reverse shoulder arthroplasty

Conditions: Proximal Humeral Fracture

Summary: this is a two steps observational study in the first part we will compare the accuracy of the commercial guide against a in-hospital designed patient specific guide. as a secondary goal, the problems detected during the design phase will be described. once the accuracy of the guide is acceptable, we will implant the glenosphere of future patients using the psg guide following the same engineering design process.

reverse shoulder arthroplasty is a treatment for both non-synthesizable fractures and arthropathy degenerative. this implant is based on two main components: glenosphere and stem. the stem in turn is integrated in its upper part by a polyethylene that reduces the friction torque between the glenosphere and the stem. correct positioning of the glenosphere is critical for functionality and survival of the implant. malpositioning of glenosphere can be related to: in recent years, given the * the scapula is a flat bone, without any reference axis; * surgical approaches expose only the glenoid cavity, with few bone landmarks; * the humerus and deltoid make access to the glenoid difficult; * the morphology of the scapula is very variable. preoperative planning even without psg improves the positioning accuracy of the guide in the glenoid. in glenoids with only a slight deformity, psgs improve the accuracy of the guide entry point (\&amp;amp;lt;1 mm error, compared to \&amp;amp;gt; 4 mm under visual control) and orientation (\&amp;amp;lt; 3◦ error compared to \&amp;amp;gt; 7◦). in glenoids with more significant deformities, planning also showed superiority.

Eligibility criteria:
inclusion criteria: * patient with proximal humerus fracture candidate for reversed shoulder arthroplasty * patient with degenerative arthropathy candidate for reversed shoulder arthroplasty exclusion criteria: * previous surgeries on the proximal humerus or glenoid * no desire to participate in the study * lack of ability to accept the study (tutored patients) * open fractures

Keywords: reverse shoulder arthroplasty patient specific guide 3d
the effect of oxytocin on the alpha cell response to hypoglycaemia in patients with type 1 diabetes

Conditions: Type 1 Diabetes

Summary: investigating the effect of oxytocin on pancreatic endocrine functions by determining glucagon secretion during hypoglycemia in participants with type 1 diabetes.

glucagonotropic effects of oxytocin will be examined in 16 participants with type 1 diabetes, during a hypoglycaemic clamp with concomitant intravenous infusion of synthetic oxytocin or placebo in a randomised, double-blinded design. this will determine the effect of oxytocin on the glucagon response to hypoglycemia. additional changes in plasma/serum concentrations of insulin, c-peptide, glucose, glucose-dependent insulinotropic polypeptid (gip) and glucagon-like peptide 1 (glp-1) will be assessed.

Eligibility criteria:
inclusion criteria: * body mass index from 19 to 30 kg/m2 * t1d (diagnosed according to the criteria of the world health organization) with hba1c \<69 mmol/mol (\<8.5%) * t1d duration of 3-30 years * c-peptide negative (stimulated c-peptide ≤ 100 pmol/l) * treatment with a stable basal-bolus or insulin pump regimen for ≥3 months exclusion criteria: * anaemia (haemoglobin below normal range) * liver disease (alanine aminotransferase (alt) and/or aspartate aminotransferase (ast) \>2 times normal values) or present hepatobiliary and/or gastrointestinal disorder(s) * kidney disease (serum creatinine above normal range) * late microvascular complications except mild non-proliferative retinopathy * regular tobacco smoking or use of other nicotine-containing products * long qtc on electrocardiogram (ecg) at screening (≥0.45 seconds) * pituitary gland disease * treatment with any glucose-lowering drugs besides insulin * any ongoing medication or physical or psychological condition that the investigator feels would interfere with trial participation
the effect of methylphenidate versus placebo on state anxiety in children with attention deficit hyperactivity disorder.

Conditions: Attention Deficit Hyperactivity Disorder

Summary: the purpose of the study is to explore the effect of methylphenidate on state anxiety in children with attention deficit hyperactivity disorder. patient population: 30 children diagnosed with attention deficit hyperactivity disorder. the subjects will be of all racial, ethnical and gender categories, ranging from 8 to 18 years of age. structure: the study is a randomized double blind crossover study. the subjects will complete a continuous performance test, the cambridge neuropsychological test automated battery, before and after given methylphenidate or placebo on the first day of the study. on the second day of the study, the subjects will receive either methylphenidate or placebo based on what was given on the first day of the study and they will complete the same task.


Eligibility criteria:
inclusion criteria: * attention deficit and hyperactivity disorder * children aged 8-18 years exclusion criteria: * pervasive developmental disorder * schizophrenia * bipolar disorder * current depressive episode * current anxiety disorder * drug use during the past 6 months

Keywords: attention deficit hyperactivity disorder methylphenidate placebo state anxiety
efficacy, safety and tolerability of romosozumab in the treatment of japanese women with postmenopausal osteoporosis

Conditions: Postmenopausal Osteoporosis (PMO)

Summary: the purpose of this study is to determine if treatment with romosozumab increases bone mineral density in japanese women with postmenopausal osteoporosis.


Eligibility criteria:
inclusion criteria: ambulatory, postmenopausal japanese women with osteoporosis (defined as bone mineral density t-score of ≤ -4.00 at the lumbar spine or bmd t-score of ≤ -3.50 at the total hip, or femoral neck) exclusion criteria: * severe osteoporosis * use of agents affecting bone metabolism * history of metabolic or bone disease (except osteoporosis) * vitamin d insufficiency (vitamin d repletion and rescreening is permitted) * current hyper- or hypocalcemia * current, uncontrolled hyper- or hypothyroidism * current, uncontrolled hyper- or hypoparathyroidism

Keywords: osteoporosis, osteoporosis-postmenopausal, bone diseases-metabolic, bone diseases, musculoskeletal diseases